高危骨髓增生异常综合征和急性髓系白血病患者接受异基因白血病来源树突状细胞疫苗 DCP-001 后获得持久缓解和生存
Durable Responses and Survival in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients Receiving the Allogeneic Leukemia-derived Den
FRONTIER PAPERS
Durable Responses and Survival in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients Receiving the Allogeneic Leukemia-derived Den
WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma.
我们的方法获得了一组天然表达的WT1肽和四个TCR,它们是在WT1表达肿瘤患者中,包括AML和卵巢癌,进行TCR基因转移策略的有前景的候选者。
Research progress on dendritic cell vaccines in cancer immunotherapy.
树突状细胞(DC)疫苗可诱导特异性免疫反应,从而选择性地清除靶细胞。
Modified Dendritic cells as a therapeutic platform in hematologic malignancies with translational insights from central nervous system tumors.
树突状细胞(DC)疫苗能引发特异性免疫反应,能够精确消除靶细胞。
Dendritic cells in hematologic malignancies: a brief review of immunoregulation to new perspectives.
树突状细胞(DCs)是免疫系统的重要哨兵,在激活初始T细胞对抗白血病细胞中发挥关键作用。
WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy.
强化诱导化疗可使>60%的急性髓系白血病(AML)患者达到完全缓解(CR),但对于不适合异基因造血干细胞移植(allo-HSCT)的复发患者,总生存期(OS)较差。
mRNA vaccines in cancer immunotherapy: current progress and perspectives in solid tumors and hematologic malignancies.
COVID-19大流行期间mRNA疫苗的空前成功加速了基于核酸的治疗方法的发展,尤其是在肿瘤学领域。
Dendritic cell vaccination strategy for the treatment of acute myeloid leukemia: a systematic review.
我们进行了一项系统综述,支持将DC疫苗疗法作为AML的有效治疗方法。该疗法在实现缓解、增强免疫系统功能和延长总生存期方面显示出潜力。然而,需要更多研究来改进DC疫苗的制备和递送方法,并确认其长期安全性和有效性。
Vaccination Therapy for Acute Myeloid Leukemia: Where Do We Stand?
免疫治疗正在改变许多血液疾病的治疗格局,其中免疫检查点抑制剂、双特异性抗体和 CAR-T 疗法是其最突出的体现。
A phase I/II feasibility vaccine study by autologous leukemic apoptotic corpse-pulsed dendritic cells for elderly AML patients.
现在需要更大规模的2期研究,以明确含白血病凋亡小体的DC疫苗在老年及年轻AML人群中的作用。
共 10 条
MEMBER ACCOUNT
登录成功会直接打开下一页。